Literature DB >> 8252810

Studies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41.

T Hidvégi1, Z Prohászka, E Ujhelyi, N M Thielens, M P Dierich, H Hampl, G Arlaud, K Nagy, G Füst.   

Abstract

We have previously demonstrated that HIV envelope gp41 binding to specific antibodies decreases after preincubation of fluid-phase gp41 in normal human serum. This inhibition is proven to be mediated by the classical complement pathway. In this study recombinant gp41 (rgp41) and/or synthetic peptides were preadsorbed to solid phase, and then complement (normal human serum/heated human serum/purified Clq/heated Clq) and anti-gp41 antibodies were added either after each other or simultaneously, and the amounts of bound antibody, and deposited C3b, C4b and Clq were measured. Complement-dependent inhibition of antibody binding to solid-phase rgp41 was found, and Clq seems to be at least partially responsible for this phenomenon. Heating of Clq did not affect this process. Higher amounts of anti-gp41 antibodies significantly and dose-dependently enhanced C4b and C3b fixation to solid-phase rgp41. In the case of synthetic peptides corresponding to the immunodominant region of gp41, significant antibody binding to the solid-phase peptides was also detected, and pretreatment of peptides preadsorbed to solid phase with normal human serum almost totally abolished the antibody binding.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8252810      PMCID: PMC1534428          DOI: 10.1111/j.1365-2249.1993.tb08223.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Complement receptors: another port of entry for HIV.

Authors:  B M Soelder; E C Reisinger; D Koefler; G Bitterlich; H Wachter; M P Dierich
Journal:  Lancet       Date:  1989-07-29       Impact factor: 79.321

2.  Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals.

Authors:  J Homsy; M Meyer; J A Levy
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

3.  Genetic locus, primary structure, and chemical synthesis of human immunodeficiency virus protease.

Authors:  T D Copeland; S Oroszlan
Journal:  Gene Anal Tech       Date:  1988 Nov-Dec

4.  Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro.

Authors:  W E Robinson; T Kawamura; D Lake; Y Masuho; W M Mitchell; E M Hersh
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

5.  FN-C1q and C1 INH C1r-C1s complexes as indicators of complement activation in patients with chronic lymphocytic leukaemia.

Authors:  T Hidvégi; G A Ermolin; E E Efremov; M M Dikov; L V Kurmanova; G V Vnashenkova; M V Merkulova; M Kókai; A Panya; G Füst
Journal:  Immunol Lett       Date:  1989-07       Impact factor: 3.685

Review 6.  HIV and human complement: mechanisms of interaction and biological implication.

Authors:  M P Dierich; C F Ebenbichler; P Marschang; G Füst; N M Thielens; G J Arlaud
Journal:  Immunol Today       Date:  1993-09

7.  Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens.

Authors:  M Reynes; J P Aubert; J H Cohen; J Audouin; V Tricottet; J Diebold; M D Kazatchkine
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

8.  Complement receptor type 2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV.

Authors:  V Boyer; C Delibrias; N Noraz; E Fischer; M D Kazatchkine; C Desgranges
Journal:  Scand J Immunol       Date:  1992-12       Impact factor: 3.487

9.  Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro.

Authors:  W E Robinson; T Kawamura; M K Gorny; D Lake; J Y Xu; Y Matsumoto; T Sugano; Y Masuho; W M Mitchell; E Hersh
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

10.  Antibody-dependent enhancement of human immunodeficiency virus type 1 infection.

Authors:  W E Robinson; D C Montefiori; W M Mitchell
Journal:  Lancet       Date:  1988-04-09       Impact factor: 79.321

View more
  7 in total

1.  Immunoglobulin and complement complexes in blood following infection with human immunodeficiency virus type 1.

Authors:  X X Peng; M A Wainberg; Y Tao; B G Brenner
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

Review 2.  Enhancing role of complement in HIV infection.

Authors:  A Mouhoub; N Thieblemont; C Delibrias; E Fischer; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

3.  Serologic reactivity of a synthetic peptide from human immunodeficiency virus type 1 gp41 with sera from a Mexican population.

Authors:  G Gevorkian; C Soler; M Viveros; A Padilla; T Govezensky; C Larralde
Journal:  Clin Diagn Lab Immunol       Date:  1996-11

4.  Role of Complement and Antibodies in the Control and Facilitation of HIV Disease.

Authors:  Zoltán Prohászka; Ferenc D Tóth; Dénes Bánhegyi; George Füst
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

5.  Heat shock protein 70 is a potent activator of the human complement system.

Authors:  Zoltán Prohászka; Mahavir Singh; Kálmán Nagy; Emese Kiss; Gabriella Lakos; Jenö Duba; George Füst
Journal:  Cell Stress Chaperones       Date:  2002-01       Impact factor: 3.667

6.  Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1.

Authors:  Z Prohászka; T Hidvégi; E Ujhelyi; H Stoiber; M P Dierich; C Süsal; G Füst
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

7.  Efficacy of HIV-specific and 'antibody-independent' mechanisms for complement activation by HIV-infected cells.

Authors:  M N Saarloos; T F Lint; G T Spear
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.